First-of-its-kind evaluation in biopsy-proven AIH: LiverMultiScan’s cT1 increases clinician confidence and influences management by improving disease characterization and early detection of patients in biochemical remission with undetected, active sub-clinical disease at a high risk of relapse, compared to VCTE and serum biomarkers alone.